Versant Capital Management Inc Acquires 157 Shares of Insulet Co. (NASDAQ:PODD)

Versant Capital Management Inc lifted its holdings in Insulet Co. (NASDAQ:PODD) by 106.1% during the 4th quarter, HoldingsChannel reports. The institutional investor owned 305 shares of the medical instruments supplier’s stock after purchasing an additional 157 shares during the period. Versant Capital Management Inc’s holdings in Insulet were worth $80,000 at the end of the most recent quarter.

Other institutional investors and hedge funds have also recently modified their holdings of the company. International Assets Investment Management LLC purchased a new stake in Insulet in the second quarter worth $32,000. Commonwealth Equity Services LLC grew its holdings in shares of Insulet by 24.7% in the second quarter. Commonwealth Equity Services LLC now owns 16,531 shares of the medical instruments supplier’s stock worth $3,336,000 after purchasing an additional 3,272 shares during the last quarter. Natixis Advisors LLC increased its stake in Insulet by 13.6% in the 2nd quarter. Natixis Advisors LLC now owns 24,607 shares of the medical instruments supplier’s stock worth $4,966,000 after buying an additional 2,955 shares during the period. Rhumbline Advisers increased its stake in Insulet by 0.5% in the 2nd quarter. Rhumbline Advisers now owns 146,561 shares of the medical instruments supplier’s stock worth $29,576,000 after buying an additional 757 shares during the period. Finally, Private Advisor Group LLC lifted its holdings in Insulet by 92.6% during the 2nd quarter. Private Advisor Group LLC now owns 3,187 shares of the medical instruments supplier’s stock valued at $643,000 after buying an additional 1,532 shares in the last quarter.

Insider Buying and Selling

In other Insulet news, CAO Lauren Budden sold 915 shares of the business’s stock in a transaction that occurred on Tuesday, December 10th. The shares were sold at an average price of $275.62, for a total transaction of $252,192.30. Following the sale, the chief accounting officer now owns 5,733 shares of the company’s stock, valued at approximately $1,580,129.46. The trade was a 13.76 % decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. 0.47% of the stock is owned by company insiders.

Insulet Price Performance

NASDAQ PODD opened at $266.30 on Friday. Insulet Co. has a 12-month low of $160.19 and a 12-month high of $279.77. The firm’s fifty day simple moving average is $260.30 and its two-hundred day simple moving average is $227.97. The company has a current ratio of 3.68, a quick ratio of 2.80 and a debt-to-equity ratio of 1.21. The firm has a market capitalization of $18.68 billion, a P/E ratio of 45.60, a P/E/G ratio of 4.12 and a beta of 1.21.

Analyst Ratings Changes

A number of equities analysts have commented on the stock. Piper Sandler upped their target price on shares of Insulet from $230.00 to $285.00 and gave the stock an “overweight” rating in a research note on Tuesday, September 17th. Sanford C. Bernstein began coverage on Insulet in a research note on Wednesday, November 6th. They issued an “outperform” rating and a $300.00 price objective on the stock. Wells Fargo & Company lifted their target price on Insulet from $290.00 to $305.00 and gave the company an “overweight” rating in a research report on Wednesday, December 11th. TD Cowen increased their price target on Insulet from $264.00 to $324.00 and gave the stock a “buy” rating in a research report on Friday. Finally, Citigroup raised their price target on Insulet from $283.00 to $310.00 and gave the company a “buy” rating in a research note on Wednesday, December 11th. Three equities research analysts have rated the stock with a hold rating and thirteen have issued a buy rating to the stock. According to MarketBeat.com, Insulet has a consensus rating of “Moderate Buy” and an average target price of $272.81.

Insulet Company Profile

Insulet Corporation develops, manufactures, and sells insulin delivery systems for people with insulin-dependent diabetes. The company's Omnipod platform includes the Omnipod 5 Automated Insulin Delivery System (Omnipod 5) which includes a proprietary AID algorithm embedded in the Pod that integrates with a third-party continuous glucose monitor to obtain glucose values through wireless bluetooth communication; Omnipod DASH that features a bluetooth enabled Pod that is controlled by a smartphone-like Personal Diabetes Manager with a color touch screen user interface; and Omnipod GO, a standalone, wearable, insulin delivery system that provides a fixed rate of continuous rapid-acting insulin for 72 hours.